Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency From Nasdaq Regarding Requirement to Timely File Annual Report On Form 10-K
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency From Nasdaq Regarding Requirement to Timely File Annual Report On Form 10-K
WOODCLIFF LAKE, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the "Company") today announced that it received a notice (the "Notice") on April 8, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") advising the Company that due to the Company's failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the "Form 10-K"), with the Securities and Exchange Commission (the "SEC"), the Company is not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires the timely filing of all required periodic reports with the SEC.
新澤西州伍德克利夫湖,2024年4月12日(GLOBE NEWSWIRE)——鷹製藥公司(納斯達克股票代碼:EGRX)(“公司”)今天宣佈,它於2024年4月8日收到納斯達克股票市場有限責任公司(“納斯達克”)上市資格部門的通知(“通知”),告知該公司,由於公司未能及時提交本財年的10-K表年度報告截至2023年12月31日(“10-K表格”),根據美國證券交易委員會(“SEC”)的要求,該公司不符合納斯達克的持續上市規定納斯達克上市規則5250(c)(1)(“規則”)下的要求,該規則要求及時向美國證券交易委員會提交所有必要的定期報告。
As previously disclosed, on November 27, 2023, the Company received a separate delinquency notification (the "Initial Notice") from the Listing Qualifications Department of Nasdaq advising the Company that due to the failure to timely file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the "Form 10-Q"), the Company is not in compliance with the Rule. In the Initial Notice, Nasdaq provided the Company 60 days, or until January 26, 2024, to submit to Nasdaq a plan to regain compliance with the Rule (the "Plan"). On February 8, 2024, following timely submission of the Plan, Nasdaq notified the Company that it was granted an extension of 180 calendar days from the due date of the Form 10-Q, or until May 13, 2024, to regain compliance with the Rule.
正如先前披露的那樣,2023年11月27日,公司收到了納斯達克上市資格部門的另一份拖欠通知(“初步通知”),通知公司,由於未能及時提交截至2023年9月30日的季度的10-Q表季度報告(“10-Q表格”),公司不遵守該規則。在初始通知中,納斯達克向公司提供了60天時間,即在2024年1月26日之前,向納斯達克提交恢復遵守該規則的計劃(“計劃”)。2024年2月8日,在及時提交計劃後,納斯達克通知公司,其獲准將10-Q表格的到期日延長180個日曆日,或延至2024年5月13日,以恢復對該規則的遵守。
The Company must submit an update to the Plan by April 23, 2024, to include the Company's plans to file the Form 10-K, and the Company plans to include in such update that the Company believes it is unlikely that it will file the Form 10-Q or the Form 10-K by the May 13, 2024, extension deadline. Pursuant to the Initial Notice, if the Company fails to regain compliance prior to the expiration of such extension period, Nasdaq would provide written notification that the Company's securities would be subject to delisting. However, in response to the Company's updated Plan, Nasdaq may determine that the Company will not be able to become current in its filing obligations by the May 13, 2024, extension deadline and could accelerate the issuance of a delisting notice. In the event the Company receives such a delisting notice, the Company may request a hearing before an independent Nasdaq Hearings Panel (the "Panel"). The hearing request would automatically stay any suspension or delisting action for 22 calendar days from the date of the delisting notification. In connection with the hearing request, the Company may request that the stay be extended through the conclusion of the hearings process and the expiration of any additional extension period granted by the Panel following the hearing.
公司必須在2024年4月23日之前提交計劃更新,以納入公司提交10-K表格的計劃,並且公司計劃在更新中納入公司認爲不太可能在2024年5月13日延期截止日期之前提交10-Q表或10-K表格的更新。根據初步通知,如果公司未能在延期期到期之前恢復合規,納斯達克將提供書面通知,說明該公司的證券將被退市。但是,針對公司更新的計劃,納斯達克可能會決定該公司將無法在2024年5月13日的延期截止日期之前履行其申報義務,並可能加快除名通知的發佈。如果公司收到此類除名通知,公司可以要求獨立的納斯達克聽證小組(“小組”)舉行聽證會。聽證請求將自除名通知之日起22個日曆日內自動暫停任何暫停或除名行動。關於聽證請求,公司可以要求在聽證會結束以及聽證會後小組批准的任何額外延期期到期後延長中止期限。
There can be no assurance that any hearing would be successful, that an extended stay or additional extension would be granted, that the Company will be able to regain compliance with the Rule or maintain compliance with the other continued listing requirements set forth in the Nasdaq Listing Rules or that the Company will be able to continue its listing on Nasdaq.
無法保證任何聽證會取得成功,無法保證延長中止期限或進一步延期,無法保證公司能夠恢復對該規則的遵守或遵守《納斯達克上市規則》中規定的其他持續上市要求,也無法保證公司能夠繼續在納斯達克上市。